AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie pending Legal Claims — Biocell Textured Breast Implant ALCL State Lawsuits (cases)
Form 10-Q / 10-K Contingencies Note
Latest, Q2 2026
475
Period ended Jun 30, 2026
Change on a year earlier
+533.3%
75 in Q2 2025
History
9 quarters
Since Q2 2024
Sources
9
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Pending Legal Claims — Biocell Textured Breast Implant ALCL State Lawsuits (cases) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 475 | +533.3% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2026 | Mar 31, 2026 | 75 | 0.0% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 75 | 0.0% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 75 | 0.0% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 75 | 0.0% | Form 10-Q (filed 2025-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 75 | – | Form 10-Q (filed 2025-05-09) ↗ |
| Q4 2024 | Dec 31, 2024 | 75 | – | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2024 | Sep 30, 2024 | 75 | – | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 75 | – | Form 10-Q (filed 2024-08-07) ↗ |
Breakdown
What makes up pending legal claims — biocell textured breast implant alcl state lawsuits (cases)
Cite this data
StockData. (2026). AbbVie Pending Legal Claims — Biocell Textured Breast Implant ALCL State Lawsuits (cases), quarterly Q2 2024–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/lit_biocell_state
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.